AdORN - Newly-Diagnosed Ovarian, Fallopian Tube, or Peritoneal Cancer - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn whether the investigational drug, atezolizumab, can be given with standard chemotherapy without delaying surgery for ovarian, fallopian tube and peritoneal cancer.
Ovarian, fallopian tube, and peritoneal cancer
Who Can Participate in the Study?
Adult females who:
- Have not had prior treatment for advanced (stage III or IV) ovarian, fallopian tube, or primary peritoneal cancer
- Are eligible to get neoadjuvant (before surgery) chemotherapy for the treatment of their cancer and will be having one or more surgical procedures
What is Involved?
If you agree to be in the study, you will:
- Get a combination of atezolizumab, paclitaxel, and carboplatin every three weeks for nine weeks
- Have surgery, followed by an additional nine weeks of atezolizumab, carboplatin, and paclitaxel
If your cancer does not get worse, you will get atezolizumab in the maintenance setting every three weeks for up to 18 months.